Luis del Peso Ovalle

ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy

A. Esparís-Ogando, A. Pandiella, M. Deininger, 2009, PloS one.